Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 4,301–4,400 of 4,628
Moore, I., Wrobel, J. P., Rhodes, J. E., Lin, Q., Webster, S. E., Jo, H., Troy, L., Grainge, C., Glaspole, I., & Corte, T. J. (2020) · Figshare · doi:10.6084/m9.figshare.13047329
Additional file 2 of Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959619
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549526
Self-citationCutolo, M., Gotelli, E., Montagna, P., Tardito, S., Paolino, S., Pizzorni, C., Sulli, A., Smith, V., & Soldano, S. (2021) · Figshare · doi:10.6084/m9.figshare.15102880
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835197
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615032
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25608744
Soldano, S., Smith, V., Montagna, P., Gotelli, E., Campitiello, R., Pizzorni, C., Paolino, S., Sulli, A., Cere, A., & Cutolo, M. (2024) · Figshare · doi:10.6084/m9.figshare.26695683
Additional file 1 of Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Nasser, M., Si-Mohamed, S., Turquier, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779877
Self-citationMarijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835200
Yamagata, A., Arita, M., Tachibana, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457401
Additional file 7 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26650107
贾钦尧, Lei, Y., Chen, S., Liu, S., Wang, T., & Cheng, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24240185
Cano-Jiménez, E., Romero Ortiz, A. D., Villar, A., Rodríguez-Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Figshare · doi:10.6084/m9.figshare.21062151
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Figshare · doi:10.6084/m9.figshare.26736267
Özaltin, B., Chapman, R., Arfeen, M. Q. U., Fitzpatick, N., Hemingway, H., Direk, K., & Jacob, J. (2024) · Figshare · doi:10.6084/m9.figshare.26736270
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615014
Zhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26036523
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24180899
Additional file 2 of Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19135954
Yang, X., Sun, W., Jing, X., Zhang, Q., Huang, H., & Xu, Z. (2022) · Figshare · doi:10.6084/m9.figshare.19565832
Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022) · Figshare · doi:10.6084/m9.figshare.21299410
Jouneau, S., Crestani, B., Thibault, R., Léderlin, M., Vernhet, L., Valenzuela, C., Wijsenbeek, M. S., Kreuter, M., Stansen, W., Quaresma, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13290619
Self-citationRautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140887
Cottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549508
Self-citationPodolanczuk, A. J., Kim, J. S., Cooper, C. B., Lasky, J. A., Murray, S., Oldham, J. M., Raghu, G., Flaherty, K. R., Spino, C., Noth, I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22611217
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549505
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227708
Self-citationAdditional file 1 of Lung function trajectories in patients with idiopathic pulmonary fibrosis
Neely, M. L., Hellkamp, A. S., Bender, S., Todd, J. L., Liesching, T. N., Luckhardt, T., Oldham, J. M., Raj, R., White, E. S., & Palmer, S. M. (2023) · Figshare · doi:10.6084/m9.figshare.24022888
Lai, X., Lin, Y., Huang, S., Pu, L., Zeng, Q., Wang, Z., & Huang, W. (2023) · Figshare · doi:10.6084/m9.figshare.24054621
Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022) · Figshare · doi:10.6084/m9.figshare.21299404
Glaspole, I., Bonella, F., Bargagli, E., Glassberg, M. K., Caro, F., Stansen, W., Quaresma, M., Orsatti, L., & Bendstrup, E. M. (2021) · Figshare · doi:10.6084/m9.figshare.14490373
Additional file 2 of Loss of ZNF451 mediates fibroblast activation and promotes lung fibrosis
Peng, H., Zhang, Y., Min, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25584052
Additional file 1 of Loss of ZNF451 mediates fibroblast activation and promotes lung fibrosis
Peng, H., Zhang, Y., Min, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25583913
Lee, J. H., Park, H. J., Kim, S., Kim, Y.-J., & Kim, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26566310
Karampitsakos, Τ., Galaris, A., Chrysikos, S., Παπαϊωάννου, Ο., Vamvakaris, I. N., Barbayianni, I., Kanellopoulou, P., Grammenoudi, S., Anagnostopoulos, N., Stratakos, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26639821
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615023
Anan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21405842
Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., & Kreuter, M. (2021) · Figshare · doi:10.6084/m9.figshare.16835206
Additional file 1 of Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
Tanaka, Y., Suzuki, Y., Hasegawa, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959616
Self-citationChoi, S. M., Mo, Y., Bang, J.-Y., Ko, Y. G., Ahn, Y. H., Kim, H. Y., Koh, J., Yim, J.-J., & Kang, H.-R. (2024) · Figshare · doi:10.6084/m9.figshare.26572882
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024700
Schweikert, A., Kenny, S., Oglesby, I. K., Glasgow, A., Santi, C. D., Gensch, I., Lachmann, N., Desroziers, T., Fletcher, C., Snijders, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24883838
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617848
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361399
Additional file 5 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26650101
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615026
Chen, T., Tsai, A. P. Y., Hur, S. A., Wong, A. W., Sadatsafavi, M., Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., Shapera, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14936197
Self-citationAnan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21405863
Jouneau, S., Crestani, B., Thibault, R., Léderlin, M., Vernhet, L., Valenzuela, C., Wijsenbeek, M. S., Kreuter, M., Stansen, W., Quaresma, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13290622
Self-citationCorral, M., DeYoung, K., & Kong, A. M. (2020) · Figshare · doi:10.6084/m9.figshare.12644635
贾钦尧, Lei, Y., Chen, S., Liu, S., Wang, T., & Cheng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.24240252
Suzuka, T., Kotani, T., Saito, T., Matsuda, S., Sato, T., & Takeuchi, T. (2022) · Figshare · doi:10.6084/m9.figshare.21299407
Jouneau, S., Crestani, B., Thibault, R., Léderlin, M., Vernhet, L., Valenzuela, C., Wijsenbeek, M. S., Kreuter, M., Stansen, W., Quaresma, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13290604
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227723
Self-citationWu, M., Wang, Z., Shi, X., Zan, D., Chen, H., Yang, S., Ding, F., Yang, L., Tan, P., Ma, R. Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24144030
Cottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549520
Self-citationCottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227738
Self-citationSchmid, U., Weber, B., Sarr, C., & Freiwald, M. (2021) · Figshare · doi:10.6084/m9.figshare.15033361
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986272
Self-citationLee, J. H., Park, H. J., Kim, S., Kim, Y.-J., & Kim, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26566307
Shimoji, K., Nakashima, T., Masuda, T., Namba, M., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Mimae, T., Miyamoto, S., Iwamoto, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24647200
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986263
Self-citationAnan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21405866
Anan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21405860
Yamagata, A., Arita, M., Tachibana, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457407
Anan, K., Kataoka, Y., Ichikado, K., Kawamura, K., Johkoh, T., Fujimoto, K., Tobino, K., Tachikawa, R., Ito, H., Nakamura, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21405869
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Figshare · doi:10.6084/m9.figshare.25608868
Additional file 3 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26650095
Cottin, V., Richeldi, L., Rosas, I., Otaola, M., Song, J. W., Sara, T., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14227705
Self-citationCottin, V., Martínez, F. J., Jenkins, G. R., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Figshare · doi:10.6084/m9.figshare.19549523
Self-citationChu, K.-A., Yeh, C.-C., Kuo, F.-H., Lin, W.-R., Hsu, C.-W., Chen, T.-H., & Fu, Y.-S. (2020) · Figshare · doi:10.6084/m9.figshare.13311121
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361408
Lin, T., Zhou, F., Mao, H., Xie, Z., & Jin, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26612405
Additional file 1 of Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers
Choi, B., Estépar, R. S. J., Godbole, S. V., Curtis, J. L., Wang, J. M., Estépar, R. S. J., Rosas, I. O., Mayers, J. R., Hobbs, B. D., Hersh, C. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26635839
Jia, Q., Lei, Y., Chen, S., Liu, S., Wang, T., & Cheng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26622283
Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11986296
Self-citationChen, C.-Y., Chen, C.-H., Wang, C.-Y., Lai, C.-C., Chao, C.-M., & Wei, Y.-F. (2021) · Figshare · doi:10.6084/m9.figshare.16625486
Schweikert, A., Kenny, S., Oglesby, I. K., Glasgow, A., Santi, C. D., Gensch, I., Lachmann, N., Desroziers, T., Fletcher, C., Snijders, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24883572
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2024) · Figshare · doi:10.6084/m9.figshare.26615020
Xu, F., Tong, Y., Yang, W., Cai, Y., Yu, M., Liu, L., & Meng, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25422324
Keow, J., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Figshare · doi:10.6084/m9.figshare.20024703
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosío, M. G., Gregori, D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14361405
贾钦尧, Lei, Y., Chen, S., Liu, S., Wang, T., & Cheng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26622286
Yamagata, A., Arita, M., Tachibana, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457398
Patel, A. S., Miller, E. R., Regis, S. M., Hunninghake, G. M., Price, L. L., Gawlik, M., McKee, A. B., Rieger-Christ, K. M., Pinto-Plata, V., Liesching, T. N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26568463
Rautajoki, T., Rantala, H. A., Sutinen, E., Saarto, T. H., Rajala, K., Pesonen, I., Hollmén, M., Myllärniemi, M., & Lehto, J. T. (2024) · Figshare · doi:10.6084/m9.figshare.27140902
Assayag, D., Brilland, B., Hudson, M., et al. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100230
Short Telomere Syndrome and Interstitial Lung Diseases: An Updated Clinical Review (2025)
Ahmed, S. (2025) · PULMON · doi:10.4103/pulmon.pulmon_26_25 · Cited by 1
Baseline characteristics from the EXCITING-ILD registry
Buschulte, K., Kabitz, H., Hagmeyer, L., Hammerl, P., Esselmann, A., Wiederhold, C., Skowasch, D., Stolpe, C., Joest, M., Veitshans, S., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002902 · Cited by 3
Ratsimandresy, R. A., Doran, E., Dengler, H. S., Headland, S. E., Wedeles, C. J., Guidi, R., Xu, D., Liu, J., Shi, Y., Wang, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.25.695625
Regulatory T cells protect against aberrant remodeling in a mouse model of pulmonary fibrosis
Murthy, A., Rodriguez, L. R., Barboza, W. R., Tomer, Y., Bui, S., Carson, P., Dimopoulos, T. T., Iyer, S., Chavez, K., Cooper, C. H., et al. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.12.004 · Cited by 3
Shared genetic architecture across fibrotic diseases
Bundgaard, J. S., Rand, S. A., Bentsen, M. S., Pedersen, O. B., Sørensen, E., Erikstrup, C., Bruun, M. T., Aagaard, B., Larsen, O. H., Dyrskjøt, L., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-8156241/v1
Çebi, I., & Yılmaz, M. (2026) · The European Research Journal · doi:10.18621/eurj.1832025
Carolan, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-025-00452-z
STL1267 inhibits myofibroblast differentiation in a TGFβ1-driven human lung fibroblast model
Prasad, C., Huang, S. K., Burris, T. P., & Sundar, I. K. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00561.2025
Zhou, X., Sima, M., Fang, Z., Cui, Y., Han, M., Wang, Y., Liu, J., Bi, Y., & Yue, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1734512 · Cited by 2
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.